3 818

Cited 21 times in

Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma

 Kim D.Y.  ;  Ahn S.H.  ;  Kim S.U.  ;  Choi S.B.  ;  Lee K.-H.  ;  Park M.S.  ;  Park J.Y.  ;  Lee D.Y.  ;  Han K.-H.  ;  Kim K.S 
 ONCOLOGY, Vol.81(3-4) : 184-191, 2011 
Journal Title
Issue Date
Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Carcinoma, Hepatocellular/drug therapy* ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/surgery* ; Chemotherapy, Adjuvant ; Cisplatin/administration & dosage ; Disease Progression ; Disease-Free Survival ; Female ; Fluorouracil/administration & dosage ; Follow-Up Studies ; Humans ; Infusions, Intra-Arterial ; Liver Neoplasms/drug therapy* ; Liver Neoplasms/pathology ; Liver Neoplasms/surgery* ; Male ; Middle Aged ; Neoplasm Recurrence, Local/prevention & control ; Prospective Studies ; Survival Rate ; Treatment Outcome ; Young Adult
Hepatocellular carcinoma ; Adjuvant therapy ; Hepatic ; arterial infusional chemotherapy
OBJECTIVES: We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection.

METHODS: Between January 2006 and December 2008, 31 HCC patients received four cycles of adjuvant HAIC with 5-FU and cisplatin via port system after curative resection. During the same period, 62 patients, who did not take any adjuvant therapy, were selected as controls.

RESULTS: Tumor characteristics, such as distribution of TNM stage, pathologic differentiation, portal vein invasion, or microscopic invasion did not differ between control and adjuvant groups. During follow-up, recurrence developed in 11 adjuvant (35.5%) and 24 control patients (38.7%; p = 0.823). Tumor progression after recurrence was the cause of death in 2 adjuvant (28.6%) and 7 control patients (38.8%; p = 0.912). The 2-year recurrence rate was 9.1% in the adjuvant group and 4.2% in the control group, with the median recurrence-free survival time being 10.5 and 7.5 months, respectively (p = 0.324). The 3-year cumulative survival rate was 73.3% in the adjuvant group and 68.3% in the control group (p = 0.355).

CONCLUSION: Adjuvant HAIC with 5-FU and cisplatin did not offer any beneficial effect on the recurrence after curative resection of HCC
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Kyung Sik(김경식) ORCID logo https://orcid.org/0000-0001-9498-284X
Kim, Do Young(김도영)
Kim, Seung Up(김승업) ORCID logo https://orcid.org/0000-0002-9658-8050
Park, Mi-Suk(박미숙) ORCID logo https://orcid.org/0000-0001-5817-2444
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Lee, Kwang Hun(이광훈)
Lee, Do Yun(이도연)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.